{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138249","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.138379+00:00","generated_at":"2026-06-02T00:50:06.051620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024","bullets":["Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.","R&D expense nearly doubled to $57.6M, driven by Phase 3 SUNRISE-3 and Phase 2 HCV trials.","Cash, equivalents, and marketable securities $541.5M, down $36.6M from year-end 2023.","Phase 3 COVID trial fully enrolled (2,221 patients in monotherapy cohort); topline results expected 2H 2024.","Phase 2 HCV lead-in cohort confirmed 98% SVR4; full Phase 2 results expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138249","json":"https://secwatch.observer/filing/0001193125-24-138249.json","markdown":"https://secwatch.observer/filing/0001193125-24-138249.md","text":"https://secwatch.observer/filing/0001193125-24-138249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/0001193125-24-138249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/d798777d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:50:06.051620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06b47711cccf06ae2a6a1ef79b61bb9851a1f689","claim":"Atea Pharmaceuticals, Inc. reported financial results for three months ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Atea Pharmaceuticals, Inc. (the \"Company\") issued a press release announcing its financial results for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524138249/0001193125-24-138249-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}